GlassScriptPhysician profile
Patricia L Wilson
NPI 1083692842
$5,332.50
in general payments reported to CMS, 2019-2025
30 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $265 · 2021: $184 · 2022: $827 · 2023: $1,235 · 2024: $716 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,175.72 | 2019-2025 | |
| Abbvie INC. | $534.26 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Sun Pharmaceutical Industries INC. | $488.74 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $461.77 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $384.27 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $365.93 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $338.09 | 2023-2025 | Sotyktu |
| Allergan, INC. | $324.63 | 2019-2022 | |
| Pfizer INC. | $217.63 | 2019-2025 | |
| Genzyme Corporation | $172.07 | 2019-2025 | |
| Lilly USA, LLC | $129.36 | 2019-2023 | Taltz |
| Amgen INC. | $124.56 | 2019-2025 | Otezla, Otezla |
| Csl Behring | $110.78 | 2019-2020 | |
| Galderma Laboratories, L.P. | $86.73 | 2019-2025 | Aklief, Epsolay, Nemluvio |
| Ucb, INC. | $76.78 | 2019-2024 | Bimzelx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $63.72 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.88 | 2019-2024 | Cabtreo |
| Biofrontera INC. | $24.26 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mylan Institutional INC. | $22.47 | 2023 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.65 | 2023 | Spevigo |
| Shire North American Group INC | $20.06 | 2019 | |
| Botanix Sb INC | $18.72 | 2025 | Sofdra |
| Kerecis Limited | $17.12 | 2022 | |
| Epi Health, LLC | $15.40 | 2020 | |
| Almirall LLC | $15.39 | 2023 | Klisyri |
| Organon LLC | $15.20 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $14.79 | 2023 | Ycanth |
| Strata Skin Sciences, INC. | $14.45 | 2023 | Xtrac |
| Dermavant Sciences, INC. | $13.81 | 2023 | Vtama |
| Mayne Pharma Commercial LLC | $13.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.